Literature DB >> 26154928

Comparison of standard and accelerated initiation of renal replacement therapy in acute kidney injury.

Ron Wald1,2, Neill K J Adhikari3, Orla M Smith2,4, Matthew A Weir5, Karen Pope6, Ashley Cohen6, Kevin Thorpe6,7, Lauralyn McIntyre8, Francois Lamontagne9, Mark Soth10, Margaret Herridge11, Stephen Lapinsky12, Edward Clark13, Amit X Garg5, Swapnil Hiremath13, David Klein2,6,14, C David Mazer2,15, Robert M A Richardson16, M Elizabeth Wilcox10, Jan O Friedrich2,14, Karen E A Burns2,14, Sean M Bagshaw17.   

Abstract

In patients with severe acute kidney injury (AKI) but no urgent indication for renal replacement therapy (RRT), the optimal time to initiate RRT remains controversial. While starting RRT preemptively may have benefits, this may expose patients to unnecessary RRT. To study this, we conducted a 12-center open-label pilot trial of critically ill adults with volume replete severe AKI. Patients were randomized to accelerated (12 h or less from eligibility) or standard RRT initiation. Outcomes were adherence to protocol-defined time windows for RRT initiation (primary), proportion of eligible patients enrolled, follow-up to 90 days, and safety in 101 fully eligible patients (57 with sepsis) with a mean age of 63 years. Median serum creatinine and urine output at enrollment were 268 micromoles/l and 356 ml per 24 h, respectively. In the accelerated arm, all patients commenced RRT and 45/48 did so within 12 h from eligibility (median 7.4 h). In the standard arm, 33 patients started RRT at a median of 31.6 h from eligibility, of which 19 did not receive RRT (6 died and 13 recovered kidney function). Clinical outcomes were available for all patients at 90 days following enrollment, with mortality 38% in the accelerated and 37% in the standard arm. Two surviving patients, both randomized to standard RRT initiation, were still RRT dependent at day 90. No safety signal was evident in either arm. Our findings can inform the design of a large-scale effectiveness randomized control trial.

Entities:  

Mesh:

Year:  2015        PMID: 26154928     DOI: 10.1038/ki.2015.184

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  28 in total

1.  Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery.

Authors:  Jaya Mishra; Catherine Dent; Ridwan Tarabishi; Mark M Mitsnefes; Qing Ma; Caitlin Kelly; Stacey M Ruff; Kamyar Zahedi; Mingyuan Shao; Judy Bean; Kiyoshi Mori; Jonathan Barasch; Prasad Devarajan
Journal:  Lancet       Date:  2005 Apr 2-8       Impact factor: 79.321

2.  Effect of timing of dialysis on mortality in critically ill, septic patients with acute renal failure.

Authors:  Daniel E Carl; Catherine Grossman; Martha Behnke; Curtis N Sessler; Todd W B Gehr
Journal:  Hemodial Int       Date:  2010-01       Impact factor: 1.812

3.  Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late.

Authors:  L G Gettings; H N Reynolds; T Scalea
Journal:  Intensive Care Med       Date:  1999-08       Impact factor: 17.440

4.  Neutrophil gelatinase-associated lipocalin at ICU admission predicts for acute kidney injury in adult patients.

Authors:  Hilde R H de Geus; Jan Bakker; Emmanuel M E H Lesaffre; Jos L M L le Noble
Journal:  Am J Respir Crit Care Med       Date:  2010-10-08       Impact factor: 21.405

5.  Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury.

Authors:  Philipp Kümpers; Carsten Hafer; Alexander Lukasz; Ralf Lichtinghagen; Korbinian Brand; Danilo Fliser; Robert Faulhaber-Walter; Jan T Kielstein
Journal:  Crit Care       Date:  2010-02-01       Impact factor: 9.097

6.  Timing of continuous renal replacement therapy and mortality in critically ill children*.

Authors:  Vinai Modem; Marita Thompson; Diane Gollhofer; Archana V Dhar; Raymond Quigley
Journal:  Crit Care Med       Date:  2014-04       Impact factor: 7.598

7.  Earlier-start versus usual-start dialysis in patients with community-acquired acute kidney injury: a randomized controlled trial.

Authors:  Tukaram E Jamale; Niwrutti K Hase; Manjunath Kulkarni; K J Pradeep; Vaibhav Keskar; Sunil Jawale; Dinesh Mahajan
Journal:  Am J Kidney Dis       Date:  2013-08-08       Impact factor: 8.860

8.  Timing of initiation of dialysis in critically ill patients with acute kidney injury.

Authors:  Kathleen D Liu; Jonathan Himmelfarb; Emil Paganini; T Alp Ikizler; Sharon H Soroko; Ravindra L Mehta; Glenn M Chertow
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-06       Impact factor: 8.237

9.  Timing of dialysis initiation in AKI in ICU: international survey.

Authors:  Charuhas V Thakar; James Rousseau; Anthony C Leonard
Journal:  Crit Care       Date:  2012-12-19       Impact factor: 9.097

10.  Impact on mortality of the timing of renal replacement therapy in patients with severe acute kidney injury in septic shock: the IDEAL-ICU study (initiation of dialysis early versus delayed in the intensive care unit): study protocol for a randomized controlled trial.

Authors:  Saber Davide Barbar; Christine Binquet; Mehran Monchi; Rémi Bruyère; Jean-Pierre Quenot
Journal:  Trials       Date:  2014-07-07       Impact factor: 2.279

View more
  78 in total

1.  Does early-start renal replacement therapy improve outcomes for patients with acute kidney injury?

Authors:  John R Prowle; Andrew Davenport
Journal:  Kidney Int       Date:  2015-10       Impact factor: 10.612

2.  Does this patient with AKI need RRT?

Authors:  Miet Schetz; Lui G Forni; Michael Joannidis
Journal:  Intensive Care Med       Date:  2015-12-21       Impact factor: 17.440

3.  Initiation and Cessation Timing of Renal Replacement Therapy in Patients with Type 1 Cardiorenal Syndrome: An Observational Study.

Authors:  Buyun Wu; Wenyan Yan; Xing Li; Xiangqing Kong; Xiangbao Yu; Yamei Zhu; Changying Xing; Huijuan Mao
Journal:  Cardiorenal Med       Date:  2017-01-20       Impact factor: 2.041

4.  Development of a Multicenter Ward-Based AKI Prediction Model.

Authors:  Jay L Koyner; Richa Adhikari; Dana P Edelson; Matthew M Churpek
Journal:  Clin J Am Soc Nephrol       Date:  2016-09-15       Impact factor: 8.237

5.  Timing of Kidney Replacement Therapy in Acute Kidney Injury.

Authors:  Alexander Zarbock; Ravindra L Mehta
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-30       Impact factor: 8.237

Review 6.  Biomarkers for the Early Detection and Prognosis of Acute Kidney Injury.

Authors:  Rakesh Malhotra; Edward D Siew
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-08       Impact factor: 8.237

Review 7.  Critical care nephrology in 2016: Managing organ dysfunction in critical care.

Authors:  Ravindra L Mehta
Journal:  Nat Rev Nephrol       Date:  2017-01-19       Impact factor: 28.314

Review 8.  The Japanese clinical practice guideline for acute kidney injury 2016.

Authors:  Kent Doi; Osamu Nishida; Takashi Shigematsu; Tomohito Sadahiro; Noritomo Itami; Kunitoshi Iseki; Yukio Yuzawa; Hirokazu Okada; Daisuke Koya; Hideyasu Kiyomoto; Yugo Shibagaki; Kenichi Matsuda; Akihiko Kato; Terumasa Hayashi; Tomonari Ogawa; Tatsuo Tsukamoto; Eisei Noiri; Shigeo Negi; Koichi Kamei; Hirotsugu Kitayama; Naoki Kashihara; Toshiki Moriyama; Yoshio Terada
Journal:  Clin Exp Nephrol       Date:  2018-10       Impact factor: 2.801

Review 9.  [Extracorporeal renal replacement therapy in acute kidney injury : Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI].

Authors:  V Schwenger; D Kindgen-Milles; C Willam; A Jörres; W Druml; D Czock; S J Klein; M Oppert; M Schmitz; J T Kielstein; A Zarbock; M Joannidis; S John
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-03-15       Impact factor: 0.840

10.  Efficacy and prognosis of continuous renal replacement therapy at different times in the treatment of patients with sepsis-induced acute kidney injury.

Authors:  Na An; Ruman Chen; Yafei Bai; Mingzhi Xu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.